Ekso Bionics Appoints Jack Glenn as Chief Financial Officer
August 13 2018 - 7:30AM
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in
exoskeleton technology for medical and industrial use, today
announced that John (Jack) Glenn has been appointed to the position
of Chief Financial Officer. Mr. Glenn brings over 25 years of
financial leadership experience within public and private companies
in the life sciences industry. Mr. Glenn replaces Max
Scheder-Bieschin, who, as previously announced, is leaving the
company.
“Jack’s extensive experience in all aspects of
finance within the life science industry will be a valuable
addition to the Ekso Bionics leadership team, especially as we
focus on continuing to improve our margins and reduce operating
expenses,” said Jack Peurach, President and Chief Executive Officer
of Ekso Bionics. “As announced in May, after eight years of
contributing to our success, Max will be moving on from the
company. On behalf of the leadership team and our Board of
Directors, I thank him for his dedicated service and wish him well
as he moves on to the next chapter in his life. While he will be
missed, we know that Jack has the expertise to step into Max’s
shoes and continue optimizing our financial position and operations
for future success.”
Previously, Mr. Glenn served as Chief Financial
Officer for Sonendo, Inc., a privately-held, venture-backed
company. His prior experience also includes serving as Chief
Financial Officer, at several other companies, including Armetheon
Corporation, a privately-held biopharmaceutical company; Solta
Medical, where he assisted in the company’s strategic acquisition
by Valeant Pharmaceutical; Cholestech, which was acquired by Alere
Medical; and Invivo Corporation, which was sold to Intermagnetics
General Corporation. Mr. Glenn received his MBA in Finance from
Santa Clara University and his B.S. in Business Administration from
the University of Nevada.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions
that amplify human potential by supporting or enhancing strength,
endurance and mobility across medical and industrial applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe. The company is
headquartered in the Bay Area and is listed on the Nasdaq Capital
Market under the symbol EKSO. For more information, visit:
www.eksobionics.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, operating results, capital expenditures, capital
structure, continued momentum in commercialization efforts,
expansion of product footprint or other financial or operational
items, (iii) the Company's future financial performance, and (iv)
the assumptions underlying or relating to any statement described
in points (i), (ii) or (iii) above. Such forward-looking statements
are not meant to predict or guarantee actual results, performance,
events or circumstances and may not be realized because they are
based upon the Company's current projections, plans, objectives,
beliefs, expectations, estimates and assumptions and are subject to
a number of risks and uncertainties and other influences, many of
which the Company has no control over. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or
cause actual results to differ materially from expected or desired
results may include, without limitation, changes resulting from the
Company’s finalization of its financial statements for and as of
the three and six months ended June 30, 2018, information or new
changes in facts or circumstances that may occur prior to the
filing of the Company’s Quarterly Report on Form 10-Q for such
period that are required to be included therein, the Company's
inability to obtain adequate financing to fund the Company's
operations and necessary to develop or enhance our technology, the
significant length of time and resources associated with the
development of the Company's products, the Company's failure to
achieve broad market acceptance of the Company's products, the
failure of the Company’s sales and marketing organization or
partners to market the Company’s products effectively, adverse
results in future clinical studies of the Company's medical device
products, the failure to obtain or maintain patent protection for
the Company's technology, failure to obtain or maintain regulatory
approval to market the Company's medical devices, lack of product
diversification, existing or increased competition, and the
Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC. To learn more
about Ekso Bionics please visit us at www.eksobionics.com. The
Company does not undertake to update these forward-looking
statements.
Media Contact:Amy
Wheeler212-867-1762awheeler@lazarpartners.com
Investor Contact: David
Carey212-867-1768dcarey@lazarpartners.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024